Genialis

“[Genialis’] approach begins with biology, and it is very different from other companies," said Debiopharm's Head of Translational Medicine Carolina Haefliger. 💡 "We thought [the approach] would be useful to solve the questions we have about biomarkers and DNA damage response agents. They may provide an answer that would normally take a lot of resources and time when you need to move a drug through the development path.” Genialis' efforts to increase the odds of clinical trial success and help promising new medicines reach patients with our novel approach to first-in-class biomarkers were recently presented in an article by Sifted. ➡️ Learn more about how Debiopharm Innovation Fund helps make this possible: https://lnkd.in/g62APAKh

Today 𝟱𝟴% of Genialis colleagues run regularly. 🏃♀️ But just 3 months ago, the number was closer to 𝟭𝟴%. How did that change so dramatically? Well, we've started a new weekly tradition. Every Friday morning, those interested take a break from work and hit the road with running coach Kristian. 💪 Stay tuned to hear how folks are progressing from 0 to 10k (with some even aiming for a half-marathon!) for a race in September.

We're joined in our mission to transform medicine through data and to develop tomorrow’s standard of care. Proud to be featured in Sifted as part of the Debiopharm Innovation Fund.

There are as many KRASi drug candidates as Wimbledon 🎾 tennis players right now. Sounds like a lot. But given the high failure rate of clinical trials, only a small handful out of ~100 will survive to compete for the cup. 📉 These odds do no favors for drug developers nor for patients. One way to change the game is to tap into the unrealized opportunities of predictive biomarkers. Read more about it in a recent article by GlobalData: https://lnkd.in/dEZG3NdD

Did you ever tag along to one of your parents' workplaces when you were little? 👧 Drawing on whiteboards, spinning on office chairs—the kids of Genialis get to do it all, too. 🙂 But once a month, they also spend some quality time with their peers at 𝗚𝗲𝗻𝗶𝗮𝗹𝗶𝘀 𝗞𝗶𝗱𝘀 𝗟𝗲𝗴𝗼 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀, building all kinds of robots. Genialis data scientist Lea Vohar leads these workshops, swapping her daily tasks of complex biological data mining for teaching these budding scientists programming and problem-solving through play. 🤖 Can't wait to continue the workshops in the fall!

Introducing Krista McKerracher, a veteran in pharma oncology development and the new Chairperson of the Genialis Board of Directors. Ms. McKerracher has dedicated her career to innovation, focusing on finding new ways to treat patients who need it most. 🙏 With nearly three decades of experience in commercial and R&D leadership at Johnson & Johnson and Novartis Oncology, she has delivered many industry firsts. 1️⃣ She launched several first-in-class drugs in the hematology/oncology space. 2️⃣ She led the team that brought the first CRISPR Cas9 ex-vivo gene editing product to the clinic (HbF edited stem cells for hemoglobinopathies). 3️⃣ And today, she joins another "first." Genialis' novel approach leverages multidimensional omics data and machine learning to develop first-in-class biomarkers that help deliver the right drug for the right patient at the right time. Read more about Ms. McKerracher and how her expertise will enhance Genialis' mission to improve patient outcomes on the link in the comments. Debiopharm, Taiwania Capital

Most biomarkers answer simple yes/no questions like: "𝘐𝘴 𝘢 𝘮𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘴𝘦𝘯𝘵?". But with the emergence of next generation biomarkers that measure complex biological patterns, we get informative answers to questions like: “𝘏𝘰𝘸 𝘭𝘪𝘬𝘦𝘭𝘺 𝘸𝘪𝘭𝘭 𝘵𝘩𝘪𝘴 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘳𝘦𝘴𝘱𝘰𝘯𝘥 𝘵𝘰 𝘵𝘢𝘳𝘨𝘦𝘵𝘦𝘥 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵?”. ✅ Find out more about these revolutionary new biomarkers, using multidimensional omics data and machine learning, at the Festival of Genomics & Biodata (June 12th - 13th) in Boston! On Wednesday, Genialis CEO Rafael Rosengarten will present on Genialis™ krasID, a first-in-class biomarker to predict clinical benefit of KRASi. 🤝 Don't miss Rafael's talk in the Live Lounge at 12:10 PM, following the presentation by AstraZeneca and preceding the one by Merck & Co. See you in our hometown! #FOGBoston Front Line Genomics Bethan Lumb

Two topics stood out above all others at #ASCO24: ��𝗥𝗔𝗦 and antibody-drug conjugates (𝗔𝗗𝗖𝘀). Our team on the ground shared these observations: ✅KRAS inhibitor combinations are showing 𝘁𝗿𝗲𝗺𝗲𝗻𝗱𝗼𝘂𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝗶𝗲𝘀 in non-small cell lung cancer (NSCLC). ↪️Combinations such as Olomorasib + Pembrolizumab and Fulzerasib + Cetuximab show 77% and 81.8% objective response rates in first-line therapy, respectively. ✅Next-gen KRAS G12C inhibitors like Glecirasib show better efficacy and fewer side effects than earlier treatments in 2nd line+ NSCLC. ✅Adagrasib's performance in NSCLC is similar to Sotorasib, with promising results across other solid tumors. ↪️This suggests that KRAS-directed biological pathways and wiring are shared between these histologies and could be effectively targeted using a multi-modular biomarker approach. ❗ADCs are gaining attention but 𝗹𝗮𝗰𝗸 𝗿𝗼𝗯𝘂𝘀𝘁 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 for targeting and payload prediction. What would you add?

As many as 𝟰 𝗼𝗳 𝟱 of the world's patient data sets come from people of European descent. How can we develop therapies for all populations if our algorithms are trained on data from mostly one group? 📈 “Relying on data that represents too narrow a population will be full of gaps and biases, which the AI and machine learning algorithms will learn,” says Genialis’ CEO Rafael Rosengarten. In a recent Forbes article, Rafael discussed how Genialis is working to change this by assembling the world's most 𝗲𝘁𝗵𝗻𝗼-𝗴𝗲𝗼𝗴𝗿𝗮𝗽𝗵𝗶𝗰𝗮𝗹𝗹𝘆 𝗱𝗶𝘃𝗲𝗿𝘀𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗮𝘁𝗮 𝘀𝗲𝘁𝘀. 🌍 Check the link in the comments to read the full article by Jennifer Kite-Powell. 📷: Mario Tama/Getty Images

Packed overflow screening room for AI and Regulatory Innovation in Healthcare panel at #bio2024 ... On stage in the other room moderator Paul Howard, PhD Alex Zhavoronkov Mida Pezeshkian, PhD and others The Alliance for Artificial Intelligence in Healthcare (AAIH)